AU2002253999A1 - Ascorbic acid analogs for metalloradiopharmaceuticals - Google Patents

Ascorbic acid analogs for metalloradiopharmaceuticals

Info

Publication number
AU2002253999A1
AU2002253999A1 AU2002253999A AU2002253999A AU2002253999A1 AU 2002253999 A1 AU2002253999 A1 AU 2002253999A1 AU 2002253999 A AU2002253999 A AU 2002253999A AU 2002253999 A AU2002253999 A AU 2002253999A AU 2002253999 A1 AU2002253999 A1 AU 2002253999A1
Authority
AU
Australia
Prior art keywords
metalloradiopharmaceuticals
ascorbic acid
acid analogs
analogs
ascorbic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002253999A
Other languages
English (en)
Inventor
Shuang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of AU2002253999A1 publication Critical patent/AU2002253999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002253999A 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals Abandoned AU2002253999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27138901P 2001-02-26 2001-02-26
US60/271,389 2001-02-26
PCT/US2002/005155 WO2002067859A2 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Publications (1)

Publication Number Publication Date
AU2002253999A1 true AU2002253999A1 (en) 2002-09-12

Family

ID=23035343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002253999A Abandoned AU2002253999A1 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Country Status (12)

Country Link
US (1) US6713042B2 (cg-RX-API-DMAC7.html)
EP (1) EP1365813A4 (cg-RX-API-DMAC7.html)
JP (1) JP2004529884A (cg-RX-API-DMAC7.html)
CN (1) CN1503680A (cg-RX-API-DMAC7.html)
AU (1) AU2002253999A1 (cg-RX-API-DMAC7.html)
BR (1) BR0207315A (cg-RX-API-DMAC7.html)
CA (1) CA2438204A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032597A3 (cg-RX-API-DMAC7.html)
HU (1) HUP0304083A2 (cg-RX-API-DMAC7.html)
IL (1) IL157359A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007595A (cg-RX-API-DMAC7.html)
WO (1) WO2002067859A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20050089471A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
JP5238496B2 (ja) * 2006-05-19 2013-07-17 日本メジフィジックス株式会社 新規アミロイド親和性化合物
WO2007148088A2 (en) * 2006-06-21 2007-12-27 Ge Healthcare Limited Radiopharmaceutical products
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
WO2008059714A1 (en) * 2006-11-17 2008-05-22 Nihon Medi-Physics Co., Ltd. Novel compounds with affinity for amyloid
CN101595108A (zh) * 2006-11-30 2009-12-02 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
US8790620B2 (en) * 2006-12-21 2014-07-29 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
EP2119458B9 (en) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
JPWO2009057577A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
US20100284912A1 (en) * 2007-12-04 2010-11-11 Bracco Diagnostics Inc. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
CA2736237A1 (en) * 2008-09-05 2010-03-11 Molecular Insight Pharmaceuticals, Inc. Pharmaceutical composition of a radioiodinated benzamide derivative and methods of making the same
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
CN102458396B (zh) 2009-04-15 2017-05-10 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
WO2013093099A1 (en) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof
US9550704B2 (en) 2012-05-24 2017-01-24 Futurechem Co., Ltd. Method for synthesizing radiopharmaceuticals using a cartridge
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
CN107207566B (zh) * 2014-11-27 2021-01-22 赛特瑞恩股份有限公司 稳定的肽缀合抗坏血酸衍生物、用于制备其的方法和包含其的化妆品组合物
TWI604853B (zh) * 2016-05-03 2017-11-11 行政院原子能委員會核能研究所 放射免疫複合體、診療劑及套組
CN107167540B (zh) * 2017-07-08 2019-07-30 万舒(北京)医药科技有限公司 测定人尿液生物样品中的DTPA-Zn的方法
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167378B (cg-RX-API-DMAC7.html) * 1972-05-08 1975-09-27
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
ATE102442T1 (de) * 1989-10-09 1994-03-15 Unilever Nv Verfahren zur herstellung von essbaren aufstrichen und anlage dafuer.
DE69231469T2 (de) * 1991-08-29 2001-01-25 Mallinckrodt Medical, Inc. Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
WO2002004030A2 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions

Also Published As

Publication number Publication date
CZ20032597A3 (cs) 2004-12-15
CN1503680A (zh) 2004-06-09
US6713042B2 (en) 2004-03-30
IL157359A0 (en) 2004-02-19
EP1365813A2 (en) 2003-12-03
JP2004529884A (ja) 2004-09-30
MXPA03007595A (es) 2003-12-04
HUP0304083A2 (hu) 2004-03-29
WO2002067859A2 (en) 2002-09-06
EP1365813A4 (en) 2006-03-22
US20020122769A1 (en) 2002-09-05
BR0207315A (pt) 2004-02-10
WO2002067859A3 (en) 2002-11-28
CA2438204A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
MXPA03007595A (es) Analogos de acido ascorbico para metalorradiofarmaceuticos.
AU2002349297A1 (en) Statin-like compounds
AU2002253675A1 (en) Chromene compound
AU2002360487A1 (en) Acyclovir-peptide analogs
AU2002357602A1 (en) Adsorbent for phosphoric acid
AU2002349677A1 (en) Chromene compound
AU2002350942A1 (en) Imidazolidineacetic acid derivatives
AU2002310684A1 (en) Vitamin D analogues
AU2001296775A1 (en) Triptycene analogs
EP1425258A4 (en) ANALOGUES OF HYDROXYEICOSENOIC ACID
AU2002329931A1 (en) Salvianolic acid b
AU6550800A (en) Hepoxilin analogs
AUPR755501A0 (en) Cyclic compound
AUPR920301A0 (en) Neurologically-active compounds
AU2002342940A1 (en) New pharmaceutical compounds
AU2004201666B2 (en) 4-Imidazolin-2-one compounds
AU2002366040A1 (en) Novel tetronic acid derivative
AUPR520201A0 (en) Antiviral compounds
AU2002244978A1 (en) Alpha-substituted omega-arylfatty acid derivative
AU2002361987A1 (en) Substituted beta-aminoalcohols used as medicaments
AU2001285801A1 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivates
AU2002314307A1 (en) Composition containing 2-aminophenylacetic acid
AU2291600A (en) New vitamin d analogs
AUPR738001A0 (en) Compound for medicinal purposes
AU2002347439A1 (en) Isobenzofuran derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase